21 completed. 19 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 19 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow V114: new trials by email Literature Review of V114 trials Research Report on V114
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) V110, V114, mRNA-1273 - Pneumococcal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 850 | 2022-01-12 | 2025-07-18 |
| Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) V114 - Pneumococcal Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 58 | 2021-02-10 | 2024-09-24 |
| V114 and Acute Otitis Media (V114-032/PNEU-ERA) V114, Pediatric vaccines - Acute Otitis Media (AOM) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 7119 | 2020-09-12 | 2026-01-22 |
| Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033) V114, PCV13 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 694 | 2020-07-01 | 2023-07-28 |
| Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 407 | 2019-11-05 | 2023-06-07 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) Rotarix™, Infanrix™ hexa, V114 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1184 | 2019-09-04 | 2023-07-28 |
| Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) V114, Prevenar 13™, Vaxelis™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1191 | 2019-08-28 | 2023-05-06 |
| Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) V114, Prevnar 13® - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 606 | 2019-06-25 | 2023-01-13 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) V114, Prevnar 13™, RotaTeq™ - Pneumococcal Infections, Pneumococcal Vaccines | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1720 | 2019-06-19 | 2023-07-28 |
| Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) V114, Prevnar 13® - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1205 | 2019-06-13 | 2021-04-26 |
| Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) V114, Prevnar 13™ - Pneumococcal Infections, Pneumonia, Pneumococcal | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2340 | 2019-06-12 | 2021-04-12 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) V114, Pneumococcal 13-valent Conjugate Vaccine (PCV13), Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV) - Pneumococcal Infections | Phase 1 | Completed | Merck Sharp & Dohme LLC | 133 | 2019-04-02 | 2025-01-15 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE) V114, Prevnar 13™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 104 | 2019-01-23 | 2021-06-16 |
| A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) V114, Prevnar 13™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2409 | 2018-12-14 | 2023-07-28 |
| A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Prevnar 13™, V114, RotaTeq™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 900 | 2018-10-18 | 2023-01-17 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) V114, QIV, Matching Placebo for V114 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1200 | 2018-09-14 | 2024-05-22 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 277 | 2018-09-12 | 2023-07-28 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1515 | 2018-07-16 | 2021-01-15 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 302 | 2018-07-06 | 2022-05-05 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 652 | 2018-06-22 | 2021-11-02 |
Showing 20 of 21. Sign in to see all of them.
Pneumococcal Infections (20) · Otitis Media (1) · Pneumonia, Pneumococcal (1)
United States (12) · Thailand (7) · Australia (5) · Canada (4) · Finland (4) · Germany (3) · Japan (3) · Poland (3) · Puerto Rico (3) · Russia (3) · Spain (3) · Taiwan (3) · Belgium (2) · Brazil (2) · Chile (2)
PMID 30427749, PMID 34489128, PMID 34507861, PMID 34750291, PMID 35039194, PMID 35146039, PMID 36150974, PMID 36383730, PMID 36522265, PMID 36621410, PMID 36841723, PMID 36882898, PMID 36939067, PMID 37105892, PMID 37309607, PMID 37338158, PMID 37344262, PMID 37846456, PMID 38497448, PMID 39384037, PMID 40006738, PMID 40537903
2018 (10), 2017 (3), 2019 (2), 2023 (1)